Doctors at the University of Washington and Fred Hutch Cancer Center have better characterized an emerging complication of chimeric antigen receptor (CAR) T-cell therapy. A recent paper in Movement ...

CAR T-cell therapy is being adapted for clear cell renal cell carcinoma, targeting CAIX and CD70 to improve efficacy and safety. Early trials like COBALT-RCC and TRAVERSE show promising disease ...

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has revolutionized how physicians treat cancer, especially blood cancers. “These patients can be cured ...

In vivo CAR T-cell therapy could revolutionize cancer treatment by bypassing traditional manufacturing, reducing costs, and minimizing adverse events. Kelonia Therapeutics' KLN-1010 has shown ...

In vivo CAR T-cell therapies could improve access by eliminating complex logistics and reducing costs, making them more accessible to underserved populations. Traditional CAR T-cell therapies face ...

HLA sensitization poses a major challenge to kidney transplantation for patients with end-stage kidney disease, especially for highly sensitized candidates. Attempts at antibody elimination ...

Manufacturing CAR T cell therapy—one of the most powerful weapons against certain blood cancers—has to date involved an elaborate process, through which doctors first extract a patient’s immune cells ...

Ever since 6-year-old Emily Whitehead became the first pediatric patient to receive CAR-T cell therapy in 2012, when T cells were removed from her body and reprogrammed to attack her leukemia before ...

AstraZeneca isn’t letting a death in a China trial detract from the potential of its $1 billion in vivo bet, even as the candidate’s safety and efficacy profile have so far failed to separate it from ...